Wafik El-Deiry, Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center at Brown University, shared a post on LinkedIn:
“My lab discovered a treatment for prostate cancer that helped some men over 90 to shrink bone metastases, reduce pain without side effects.”
Title: Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration
Authors: Mark N. Stein, Jyoti Malhotra, Rohinton S. Tarapore, Usha Malhotra, Wafik S. El-Deiry, Andrew Zloza
You can read the Full Article on BMJ Journals
“And our preclinical work of combination therapy awaits translation”
Title: Synergistic combination therapy with ONC201 or ONC206, and enzalutamide or darolutamide in preclinical studies of castration-resistant prostate cancer
Authors: Laura Jinxuan Wu, Maximilian Pinho-Schwermann, Lanlan Zhou, Leiqing Zhang, Kelsey E Huntington, Ryan Malpass, Attila A Seyhan, Benedito A Carneiro, Wafik S El-Deiry
You can read the Full Article on American Journal of Cancer Research
“And additional preclinical work”
Title: Neuroendocrine prostate cancer drivers SOX2 and BRN2 confer differential responses to imipridones ONC201, ONC206, and ONC212 in prostate cancer cell lines
Authors: Connor Purcell, Praveen R Srinivasan, Maximilian Pinho-Schwermann, William J MacDonald, Elizabeth Ding, Wafik S El-Deiry
You can read the Full Article on American Journal of Translational Research
“And of course there is radio-ligand therapy assuming PSMA+ ”
More posts featuring Wafik El-Deiry
